Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 莫树锦教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1111/j.1440-1843.2010.01821.x |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/12WOS source URL
Scopushttp://aims.cuhk.edu.hk/converis/portal/Publication/15Scopus source URL
其它资讯
摘要Lung cancer remains one of the most fatal illnesses. Recent development in cancer genomics and molecular targeted therapy leads to a paradigm shift in management of advanced-stage non-small cell lung cancer. Patients with activated mutation of epidermal growth factor receptor (EGFR) responded dramatically to EGFR tyrosine kinase inhibitor such as gefitinib or erlotinib. Multiple randomized studies have showed EGFR tyrosine kinase inhibitor to be superior to standard first-line chemotherapy in this biomarker-selected population. As the vasculature is considered to be the 'Achillus heel' of the tumour, anti-angiogenic treatment is considered to be a suitable target. Inhibition of vascular endothelial growth factor may improve the efficacy of chemotherapy, although a practical biomarker has not been identified. We have entered an era of personalized therapy for lung cancer and this evolvement holds great promises for better treatment in future. ? 2010 The Authors Respirology ? 2010 Asian Pacific Society of Respirology.
着者Lam K.-C., Mok T.S.
期刊名称Respirology
出版年份2011
月份1
日期1
卷号16
期次1
出版社Blackwell Publishing Inc.
出版地United Kingdom
页次13 - 21
国际标準期刊号1323-7799
电子国际标準期刊号1440-1843
语言英式英语
关键词Anti-angiogenesis, Bevacizumab, Epidermal growth factor receptor, Gefitinib, Lung cancer
